Chromogranin A: As A Tumor Marker for Neuroendocrine Tumors Diagnosis, Follow-up & Its Correlation with Response to Somatostatin Analogues

  • Manwar A. Mohammed AL-Naqqash Dept. of Surgery, college of medicine, University of Baghdad.
Keywords: neuroendocrine tumors, chromogranin A, somatostatin analogues.

Abstract

Background: Chromogranin A is a useful tumor marker for neuroendocrine tumors (NETs) diagnosis & follow-up, Octreotide (somatostatin-long acting repeatable (SAS-LAR)) is an established treatment for NETs. Studies regarding the relation between response to SAS-LAR & the change in Chromogranin A (CgA) plasma level are still lacking.
Objectives: To determine the association between the using of Octreotide (SAS-LAR) and CgA level on time sequence & clinical status.
Patients & methods: a prospective observational study included 38 neuroendocrine patients in The Oncology Teaching Hospital/medical city complex/Baghdad, started at September 2013 till May 2016; assessing their circulating chromogranin A (CgA) plasma levels on multiple occasions(0,2 and 4 months) by ELISA technique and its correlation with response to somatostatin analogues (SAS-LAR) in those patients.
Results: the study recruited 38 neuroendocrine patients. 21 (55%) of them were males, 23 (60%) patients were older than 50 years old & 17 (44%) had metastasis to different sites. Somatostatin analogues (octreotide 30mg) was administered to 20 out of 38 (52.6%) studied patients. Serial CgA tests were performed in (17 out of 20) patients used SAS-LAR, with a change in mean value from (225.3 U/L) pre-using the agent to (17.5 U/L) two months after its use & to (8.7 U/L) four months after its use (p=0.009, p=0.002 respectively) while the change in mean of CgA level was from (205.9 U/L) to (200.9 U/L) in 10 patients who did not use Octreotide (p=0.2).Also results showed that no statistically significant difference in mean value of CgA pre & two months after using Octreotide with regard to grade of the tumor.
Conclusions: Plasma CgA is a reliable marker for NETs (regarding diagnosis, prognosis and response to treatment including somatostatin analogues).All patients with NETs should undergo a baseline plasma CgA level at diagnosis. Serial assessment of circulating CgA could be done for NET patients when there is baseline elevation of CgA level in circulation

Downloads

Download data is not yet available.
Published
2016-01-03
How to Cite
1.
Mohammed AL-Naqqash M. Chromogranin A: As A Tumor Marker for Neuroendocrine Tumors Diagnosis, Follow-up & Its Correlation with Response to Somatostatin Analogues. JFacMedBagdad [Internet]. 3Jan.2016 [cited 11May2021];58(4):307-11. Available from: https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/270